Recent Insider Transactions • May 18
Chairman & Senior Independent Director recently bought kr52k worth of stock On the 15th of May, Anne-Sophie d'Andlau bought around 7k shares on-market at roughly kr8.01 per share. This transaction amounted to 41% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Anne-Sophie's only on-market trade for the last 12 months. Reported Earnings • Apr 24
First quarter 2026 earnings released First quarter 2026 results: Revenue: €3.24m (down 8.9% from 1Q 2025). Net income: €58.4k (up €465.1k from 1Q 2025). Profit margin: 1.8% (up from net loss in 1Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 90 percentage points per year, which is a significant difference in performance. New Risk • Mar 31
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 8.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 47% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (8.9% average weekly change). Market cap is less than US$100m (kr149.6m market cap, or US$15.6m). Reported Earnings • Mar 02
Full year 2025 earnings released: €0.41 loss per share (vs €0.40 loss in FY 2024) Full year 2025 results: €0.41 loss per share (further deteriorated from €0.40 loss in FY 2024). Revenue: €13.5m (down 16% from FY 2024). Net loss: €6.61m (loss widened 2.4% from FY 2024). Revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 77 percentage points per year, which is a significant difference in performance. Annonce • Feb 16
Physitrack PLC, Annual General Meeting, May 26, 2026 Physitrack PLC, Annual General Meeting, May 26, 2026, at 09:30 W. Europe Standard Time. Board Change • Jan 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. Chairman & Senior Independent Director Anne-Sophie d'Andlau was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 22
Third quarter 2025 earnings released: €0.02 loss per share (vs €0.023 loss in 3Q 2024) Third quarter 2025 results: €0.02 loss per share (improved from €0.023 loss in 3Q 2024). Revenue: €3.46m (down 11% from 3Q 2024). Net loss: €354.4k (loss narrowed 5.8% from 3Q 2024). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 71 percentage points per year, which is a significant difference in performance. Reported Earnings • Jul 25
Second quarter 2025 earnings released: €0.01 loss per share (vs €0.029 loss in 2Q 2024) Second quarter 2025 results: €0.01 loss per share (improved from €0.029 loss in 2Q 2024). Revenue: €3.51m (down 11% from 2Q 2024). Net loss: €150.4k (loss narrowed 68% from 2Q 2024). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 41 percentage points per year, which is a significant difference in performance. Reported Earnings • May 02
First quarter 2025 earnings released: €0.03 loss per share (vs €0.007 loss in 1Q 2024) First quarter 2025 results: €0.03 loss per share (further deteriorated from €0.007 loss in 1Q 2024). Revenue: €3.56m (down 14% from 1Q 2024). Net loss: €406.7k (loss widened 267% from 1Q 2024). Revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 33% per year whereas the company’s share price has fallen by 30% per year. Annonce • Apr 08
Physitrack PLC, Annual General Meeting, Jun 27, 2025 Physitrack PLC, Annual General Meeting, Jun 27, 2025. Reported Earnings • Apr 02
Full year 2024 earnings released: €0.40 loss per share (vs €0.17 profit in FY 2023) Full year 2024 results: €0.40 loss per share (down from €0.17 profit in FY 2023). Revenue: €16.2m (up 9.7% from FY 2023). Net loss: €6.45m (down 329% from profit in FY 2023). Revenue is forecast to grow 9.1% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 35% per year, which means it is significantly lagging earnings. Annonce • Mar 25
Physitrack plc Announces Chief Financial Officer Changes Physitrack PLC announced that Chief Financial Officer Charlotte Goodwin will be going on maternity leave starting April 1, 2025. During her leave, Matt Poulter, Deputy CFO and a key member of the Group Finance team for the past four years, will step in as Interim CFO. Matt Poulter has played a pivotal role in Physitrack's financial leadership, bringing extensive experience and a deep understanding of the company's operations. His expertise ensures a seamless transition, maintaining the company's strong financial oversight. Annonce • Mar 06
Physitrack Plc Launches Enhanced PhysiAssistant App with New Filming & Exercise Upload Feature Physitrack Plc announced the launch of a major enhancement to its PhysiAssistant app, a mobile solution designed to give healthcare providers greater flexibility in day-to-day patient care. The new patient filming and exercise upload feature enables clinicians to record and upload personalized exercise demonstrations, allowing for an unprecedented level of ultra-personalization in rehabilitation and treatment plans. The PhysiAssistant app, already a key tool for healthcare professionals, features a streamlined user interface for exercise prescription, making it possible to work hands-free with patients in a clinical setting. With today's update, practitioners can now capture video of exercises in real-time and seamlessly integrate them into the Physitrack ecosystem for onward prescription. The update also brings added benefits for patients, who can now view themselves performing exercises with professional guidance, helping them perfect their form and, in some cases, achieve more effective recovery outcomes. This launch is part of a broader series of innovations that Physitrack has introduced to its ecosystem in recent months, reinforcing its commitment to enhancing customer value and staying ahead in the digital healthcare space. Reported Earnings • Mar 02
Full year 2024 earnings released: €0.40 loss per share (vs €0.20 profit in FY 2023) Full year 2024 results: €0.40 loss per share (down from €0.20 profit in FY 2023). Revenue: €16.2m (up 6.6% from FY 2023). Net loss: €6.45m (down 301% from profit in FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 15% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has fallen by 32% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Feb 18
Investor sentiment improves as stock rises 31% After last week's 31% share price gain to kr13.20, the stock trades at a trailing P/E ratio of 6.8x. Average forward P/E is 49x in the Healthcare Services industry in Europe. Total loss to shareholders of 70% over the past three years. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to kr9.64, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 17x in the Healthcare Services industry in Europe. Total loss to shareholders of 81% over the past three years. Reported Earnings • Nov 13
Third quarter 2024 earnings released: €0.02 loss per share (vs €0.015 loss in 3Q 2023) Third quarter 2024 results: €0.02 loss per share (further deteriorated from €0.015 loss in 3Q 2023). Revenue: €3.89m (flat on 3Q 2023). Net loss: €376.2k (loss widened 57% from 3Q 2023). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 120% per year but the company’s share price has fallen by 45% per year, which means it is significantly lagging earnings. New Risk • Nov 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 6.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (6.5% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr195.9m market cap, or US$18.0m). Valuation Update With 7 Day Price Move • Nov 12
Investor sentiment deteriorates as stock falls 22% After last week's 22% share price decline to kr9.40, the stock trades at a trailing P/E ratio of 4.5x. Average forward P/E is 16x in the Healthcare Services industry in Europe. Total loss to shareholders of 82% over the past three years. Recent Insider Transactions • Oct 07
Chairman & Senior Independent Director recently bought kr51k worth of stock On the 4th of October, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr12.83 per share. This transaction amounted to 33% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anne-Sophie has been a buyer over the last 12 months, purchasing a net total of kr108k worth in shares. Reported Earnings • Aug 18
Second quarter 2024 earnings released: €0.029 loss per share (vs €0.015 loss in 2Q 2023) Second quarter 2024 results: €0.029 loss per share (further deteriorated from €0.015 loss in 2Q 2023). Revenue: €3.96m (up 5.5% from 2Q 2023). Net loss: €471.0k (loss widened 87% from 2Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Over the last 3 years on average, earnings per share has increased by 106% per year but the company’s share price has fallen by 39% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Jun 17
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to kr18.10, the stock trades at a trailing P/E ratio of 8.3x. Average forward P/E is 18x in the Healthcare Services industry in Europe. Total loss to shareholders of 62% over the past three years. Recent Insider Transactions • Jun 03
Chairman & Senior Independent Director recently bought kr57k worth of stock On the 30th of May, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr14.14 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Anne-Sophie has been a buyer over the last 12 months, purchasing a net total of kr89k worth in shares. Reported Earnings • May 15
First quarter 2024 earnings released: €0.01 loss per share (vs €0.004 loss in 1Q 2023) First quarter 2024 results: €0.01 loss per share (further deteriorated from €0.004 loss in 1Q 2023). Revenue: €4.12m (up 10% from 1Q 2023). Net loss: €110.8k (loss widened 69% from 1Q 2023). Revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Valuation Update With 7 Day Price Move • May 11
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to kr16.30, the stock trades at a trailing P/E ratio of 7.1x. Average forward P/E is 19x in the Healthcare Services industry in Europe. Negligible returns to shareholders over past year. New Risk • Mar 07
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 4,900% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (kr200.0m market cap, or US$19.4m). Valuation Update With 7 Day Price Move • Mar 06
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to kr12.60, the stock trades at a trailing P/E ratio of 5.7x. Average forward P/E is 17x in the Healthcare Services industry in Sweden. Total loss to shareholders of 17% over the past year. Reported Earnings • Mar 01
Full year 2023 earnings released: EPS: €0.20 (vs €0.006 in FY 2022) Full year 2023 results: EPS: €0.20 (up from €0.006 in FY 2022). Revenue: €15.2m (up 21% from FY 2022). Net income: €3.20m (up €3.11m from FY 2022). Profit margin: 21% (up from 0.7% in FY 2022). The increase in margin was primarily driven by higher revenue. Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden. Annonce • Feb 13
Physitrack PLC, Annual General Meeting, May 03, 2024 Physitrack PLC, Annual General Meeting, May 03, 2024. New Risk • Nov 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr268.3m market cap, or US$25.7m). Reported Earnings • Nov 15
Third quarter 2023 earnings released: €0.01 loss per share (vs €0.001 profit in 3Q 2022) Third quarter 2023 results: €0.01 loss per share (down from €0.001 profit in 3Q 2022). Revenue: €3.85m (up 14% from 3Q 2022). Net loss: €240.2k (down €256.8k from profit in 3Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 19% growth forecast for the Healthcare Services industry in Sweden. Reported Earnings • Aug 17
Second quarter 2023 earnings released: €0.015 loss per share (vs €0.026 loss in 2Q 2022) Second quarter 2023 results: €0.015 loss per share (improved from €0.026 loss in 2Q 2022). Revenue: €3.75m (up 23% from 2Q 2022). Net loss: €251.7k (loss narrowed 40% from 2Q 2022). Revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Healthcare Services industry in Sweden. New Risk • Aug 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Swedish stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (kr269.1m market cap, or US$24.8m). Annonce • Aug 15
Physitrack plc Announces Board Changes Physitrack PLC appointed Mrs. Anne-Sophie D'Andlau, formerly Vice Chair, as Chair of the Board with effect from September 15, 2023. Anne-Sophie will be replacing Mrs. Elaine Sullivan who has decided to resign from her position as an independent non-executive director and the Chair of the Board with effect from 15 September, 2023 to consider other opportunities. Elaine Sullivan has served as an independent non-executive director and the Chair of the Board since March 9, 2021, seeing the Company through its successful transition into a Plc and initial public offering on the Nasdaq First North Growth Premier Market on 18 June 2021. Annonce • Jun 03
Physitrack PLC Announces Appointment of Jack Goodwin as Head of People Physitrack PLC announced the appointment of Mr. Jack Goodwin as Head of People for the Physitrack Group. Mr. Goodwin joins the Company from the UK Government's Cabinet Office, where he last oversaw a transformation programme for 330,000 employees under the Arm's-Length Bodies and was responsible for policy advice to the Cabinet Office and His Majesty's Treasury Ministers. The appointment of Mr. Goodwin to oversee everything People and HR related provides the Company with an opportunity to streamline the company at Group level for operational and financial efficiency and Physitrack therefore at the same time also announces that it will reduce its C-suite with two people, whose roles overlap significantly with that of the Head of People function. Further to the appointment of Jack Goodwin, departing the C-suite as of but remaining with the Company for a transition period are Mr. Andrew Knox, Group Chief Operating Officer and Mr. Ryan Ebert, Chief Commercial Officer, Wellness. Ryan and Andrew will both ensure a smooth handover to Mr. Goodwin as the Physitrack Group continues on its journey. Annonce • May 04
Physitrack PLC Approves Election of Anne-Sophie D'andlau as Director Physitrack PLC approved election of Anne-Sophie D'Andlau as a Director of the Company at the Annual General Meeting held on May 3, 2023. Reported Earnings • May 03
First quarter 2023 earnings released First quarter 2023 results: Revenue: €3.73m (up 45% from 1Q 2022). Net loss: €65.6k (loss narrowed 55% from 1Q 2022). Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Recent Insider Transactions • Apr 05
Independent Non-Executive Director recently bought kr56k worth of stock On the 31st of March, Anne-Sophie d'Andlau bought around 4k shares on-market at roughly kr13.92 per share. This trade did not impact their existing holding. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold kr10.0m more in shares than they bought in the last 12 months. Major Estimate Revision • Mar 31
Consensus EPS estimates upgraded to €0.025 loss The consensus outlook for fiscal year 2022 has been updated. 2022 losses forecast to reduce from -€0.037 to -€0.025 per share. Revenue forecast steady at €12.4m. Healthcare Services industry in Sweden expected to see average net income growth of 176% next year. Consensus price target broadly unchanged at kr40.13. Share price rose 12% to kr14.50 over the past week. Reported Earnings • Mar 02
Full year 2022 earnings released: EPS: €0.01 (vs €0.06 loss in FY 2021) Full year 2022 results: EPS: €0.01 (up from €0.06 loss in FY 2021). Revenue: €12.5m (up 60% from FY 2021). Net income: €92.3k (up €907.4k from FY 2021). Profit margin: 0.7% (up from net loss in FY 2021). The move to profitability was driven by higher revenue. Revenue is forecast to grow 21% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Healthcare Services industry in Sweden. Annonce • Jan 27
Physitrack PLC Appoints Nick McClelland to Take on A New Role as Chief Growth Officer Physitrack PLC appointed Nick McClelland from Mercer to take on a new role as Chief Growth Officer of Champion Health with the objective of further accelerating the growth of Group's B2B Wellness division. Nick McClelland will lead and build on Champion Health's sales team for B2B sales of Champion's rapidly growing Employee Wellbeing solution to Enterprises as well as further develop Group level business development to continue accelerating the growth of both Champion Health and the Physitrack Group. Prior to joining Champion Health, Nick McClelland was Chief Growth Officer of Mercer UK, part of $82 billion market capitalisation global insurance giant Marsh McLennan, and prior to that led the commercial efforts of JLT Employee Benefits and Thompsons Online Benefits, which provided technology-led employee benefit and wellness solutions to Enterprises globally before both companies were acquired by Mercer. Nick is set to commence in his new role on 1 February 2023. Board Change • Jan 01
High number of new and inexperienced directors There are 4 new directors who have joined the board in the last 3 years. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. Co-Founder, CEO & Executive Director Henrik Molin is the most experienced director on the board, commencing their role in 2012. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model. Annonce • Dec 21
Physitrack PLC Announces the Appoints Anne-Sophie d'Andlau as Board Member Physitrack PLC announced the appointment of Mrs. Anne-Sophie d'Andlau to the board of directors as an independent non-executive director, effective immediately. Mrs. d'Andlau has also been appointed as a member of Physitrack Plc's nomination and audit committees. Anne-Sophie d'Andlau is the co-founder of CIAM, a corporate events-focused investment management firm that takes an active approach to equity-based investment strategies. Prior to co-founding CIAM, Anne-Sophie was the Head of Event Driven Strategies at Systeia Capital Management in Paris 2001-2008. Prior to that, Anne-Sophie spent six years with PwC in Paris and New York focused on audit, due diligence and M&A advisory. She has a degree in Corporate Finance from NEOMA Business School. Reported Earnings • Nov 08
Third quarter 2022 earnings released: EPS: €0.001 (vs €0.07 loss in 3Q 2021) Third quarter 2022 results: EPS: €0.001 (up from €0.07 loss in 3Q 2021). Revenue: €3.37m (up 69% from 3Q 2021). Net income: €16.7k (up €898.8k from 3Q 2021). Profit margin: 0.5% (up from net loss in 3Q 2021). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Healthcare Services industry in Sweden. Annonce • Aug 31
Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC acquired an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC for €1 million. Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC acquired an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC for €1 million on August 29, 2022. Under the terms of the transaction, Henrik Molin acquired 0.7 million shares Physitrack PLC from Nathan Skwortsow. As a result of the transaction, Henrik Molin boosts its ownership to 24.7% and reduces Nathan Skwortsow’s ownership to 17.8%. in Physitrack PLC.Henrik Molin, Chief Executive Officer and Co-founder of Physitrack PLC completed the acquisition of an additional 4.3% stake in Physitrack PLC (OM : PTRK) from Nathan Skwortsow, co-founder of Physitrack PLC on August 29, 2022. Reported Earnings • Aug 25
Second quarter 2022 earnings released: €0.02 loss per share (vs €0.011 loss in 2Q 2021) Second quarter 2022 results: €0.02 loss per share (down from €0.011 loss in 2Q 2021). Revenue: €3.05m (up 76% from 2Q 2021). Net loss: €421.0k (loss widened 240% from 2Q 2021). Over the next year, revenue is forecast to grow 48%, compared to a 16% growth forecast for the Healthcare Services industry in Sweden. Annonce • Aug 11
Physitrack plc Recruits Announces Management Changes Physitrack PLC boosts its management team and recruits Michal Wegrzyn from Zendesk. Michal Wegrzyn will take on a new role as Head of Engineering at Physitrack. As a result of the recruitments, co-founder and CTO Nathan Skwortsow will take on a new position focused on sourcing and developing new business ventures on behalf of the company. Michal Wegrzyn, who prior to joining Physitrack was an Engineering Manager at NYSE-listed$10bln market leader in customer support SaaS provider Zendesk, has been recruited as Head of Engineering. Michal will lead a new team of in-house Ruby on Rails, Mobile and DevOps developers, as Physitrack transitions away from its previous inhouse/outsource hybrid software development model. The new setup will not only benefit Physitrack from an efficiency and cultural standpoint but will also optimize the cost of investments in Physitrack's platform.As a result of the recruitments, co-founder and CTO Nathan Skwortsow will take on a new position in Physitrack's management team focused on sourcing and developing new business ventures on behalf of the company. Recent Insider Transactions • Jun 03
Chief Operating Officer recently bought kr56k worth of stock On the 30th of May, Andrew Knox bought around 1k shares on-market at roughly kr42.99 per share. This was the largest purchase by an insider in the last 3 months. Andrew has been a buyer over the last 12 months, purchasing a net total of kr108k worth in shares. Reported Earnings • May 26
First quarter 2022 earnings: Revenues miss analyst expectations First quarter 2022 results: Revenue: €2.58m (up 63% from 1Q 2021). Net loss: €145.7k (down 177% from profit in 1Q 2021). Revenue missed analyst estimates by 2.9%. Over the next year, revenue is forecast to grow 58%, compared to a 19% growth forecast for the industry in Sweden. Annonce • May 08
Physitrack PLC (OM:PTRK) acquired Champion Health Ltd from Harry Bliss and Ricky Bailey for £10.4 million. Physitrack PLC (OM:PTRK) acquired Champion Health Ltd from Harry Bliss and Ricky Bailey for £10.4 million on May 6, 2022. Physitrack will pay a total cash consideration of £2.5 million upfront for the acquisition, and a further potential aggregate earn-out consideration of up to £7.894 million over four years, subject to Champion achieving stretching growth and profitability targets in that period. The deal is financed with cash. Post-completion, Champion's successful wellbeing platform and innovative technology will continue to be accessible as a standalone product and will over time see the integration of Physitrack's Access ecosystem. Champion Health Ltd had gross assets of €0.3 million (£0.25 million) and revenue of €0.1 million (£0.08 million) for the year ended December 31, 2021. The management team of Champion, including co-founders Harry Bliss, Chief Executive Officer of Champion and Ricky Bailey, Chief Development Officer of Champion, their team of wellbeing and tech experts, as well as their network of skilled contributors and certified health practitioners will join Physitrack. The closing of the transaction is not subject to any closing conditions, including no regulatory approvals. The acquisition of Champion is a financially accretive deal. Paul Berwin and team of Berwins LLP acted as legal advisor to the founder shareholders.
Physitrack PLC (OM:PTRK) completed the acquisition of Champion Health Ltd from Harry Bliss and Ricky Bailey on May 6, 2022. Reported Earnings • Mar 01
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: €0.06 loss per share (down from €0.069 profit in FY 2020). Revenue: €7.81m (up 156% from FY 2020). Net loss: €815.0k (down 218% from profit in FY 2020). Revenue exceeded analyst estimates by 1.6%. Earnings per share (EPS) missed analyst estimates. Over the next year, revenue is forecast to grow 60%, compared to a 17% growth forecast for the industry in Sweden. Recent Insider Transactions • Feb 26
Chief Financial Officer recently bought kr62k worth of stock On the 24th of February, Charlotte Goodwin bought around 1k shares on-market at roughly kr45.00 per share. This was the largest purchase by an insider in the last 3 months. This was Charlotte's only on-market trade for the last 12 months. Reported Earnings • Jan 27
Full year 2021 earnings: EPS exceeds analyst expectations Full year 2021 results: €0.05 loss per share (down from €0.069 profit in FY 2020). Revenue: €7.72m (up 153% from FY 2020). Net loss: €635.0k (down 192% from profit in FY 2020). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 75%. Over the next year, revenue is forecast to grow 48%, compared to a 19% growth forecast for the industry in Sweden. Annonce • Jan 27
Physitrack PLC Provides Earnings Guidance Physitrack PLC announced that the company's aims to achieve annual organic sales growth exceeding 30% in the medium term, further supplemented by impact from future add-on acquisitions. Valuation Update With 7 Day Price Move • Jul 04
Investor sentiment improved over the past week After last week's 21% share price gain to €50.40, the stock trades at a trailing P/E ratio of 72.3x. Average trailing P/E is 45x in the Healthcare Services industry in Europe. Annonce • Jun 19
Physitrack PLC has completed an IPO in the amount of SEK 175 million. Physitrack PLC has completed an IPO in the amount of SEK 175 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 4,375,000
Price\Range: SEK 40 
